Patrick Grant Northup

Patrick Grant Northup

Auto-generated profile, based on publicly available information

Patrick Grant Northup

NYU Langone Health, New York, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Hepatology
Verified
Journal Article
Closed access
PDF file
PNPatrick G. Northup
Patrick G. Northup
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán
GGGuadalupe Garcia‐Tsao
Guadalupe Garcia‐Tsao
NINicolas M. Intagliata
Nicolas M. Intagliata
RSRiccardo A. Superina
Riccardo A. Superina
DVDominique C. Valla
Dominique C. Valla

1 August 2005 in Annals of Surgery
Verified
Journal Article
Closed access
PNPatrick G. Northup
Patrick G. Northup
RWRyan C. Wanamaker
Ryan C. Wanamaker
VLVanessa D. Lee
Vanessa D. Lee
RAReid B. Adams
Reid B. Adams
CBCarl L. Berg
Carl L. Berg
We sought to determine the ability of the Model for End-Stage Liver Disease (MELD) score to predict 30-day postoperative mortality for patients with cirrhosis undergoing nontransplant surgical procedures. The Child-Pugh class historically has been used by clinicians to assist in management decisions involving patients with cirrhosis. However, this classification scheme has a number of limitations. Recently, MELD was introduced. It has been shown to be highly predictive of mortality in a variety of clinical scenarios. Adult patients with a diagnosis of cirrhosis undergoing nontransplant surgical procedures between January 1, 1996, and January 1, 2002, at a single center were analyzed. The preoperative MELD score was calculated for all patients, and the MELD's performance in predicting 30-day mortality was determined using multivariate regression techniques. A total of 140 surgical procedures were identified and analyzed. The 30-day mortality rate was 16.4%. The mean admission MELD score for the patients who died (23.3, 95% confidence interval 19.6–27.0) was significantly different from those patients surviving beyond 30 days (16.9, 15.6–18.2), P = 0.0003. The c-statistic for MELD score predicting 30-day mortality was 0.72. Further subgroup analysis of 67 intra-abdominal surgeries showed an in-hospital mortality of 23.9%. The mean MELD score for patients dying (24.8, 20.4–29.3) was significantly different from survivors (16.2, 14.2–18.2), P = 0.0001. The c-statistic for this subgroup was 0.80. The MELD score, as an objective scale of disease severity in patients with cirrhosis, shows promise as being a useful preoperative predictor of surgical mortality risk.

1 September 2013 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PNPatrick G. Northup
Patrick G. Northup
SCStephen H. Caldwell
Stephen H. Caldwell

4 July 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
PNPatrick Grant Northup
Patrick Grant Northup
NINicolas Michael Intagliata
Nicolas Michael Intagliata
NSNeeral Lalit Shah
Neeral Lalit Shah
SPShawn Joseph Pelletier
Shawn Joseph Pelletier
CBCarl Lansing Berg
Carl Lansing Berg
CACurtis Kent Argo
Curtis Kent Argo
The Model for End‐Stage Liver Disease (MELD) allocation system for liver transplantation provides “exceptions” for diseases such as hepatocellular carcinoma (HCC). It was the aim of this study to assess equipoise between exception candidates and nonexception candidates on the waiting list and to assess if the exception system contributes to steadily increasing regional MELD at transplant. In all, 78,595 adult liver transplant candidates between January 2005 and December 2012 were analyzed. Yearly trends in waiting list characteristics and transplantation rates were analyzed for statistical association with MELD exceptions. Regional variations in these associations and the effect of exceptions on regional MELD scores at transplant were also analyzed. 27.29% of the waiting list was occupied by candidates with exceptions. Candidates with exceptions fared much better on the waiting list compared to those without exceptions in mean days waiting (HCC 237 versus non‐HCC 426), transplantation rates (HCC 79.05% versus non‐HCC 40.60%), and waiting list death rates (HCC 4.49% versus non‐HCC 24.63%). Strong regional variation in exception use occurred but exceptions were highly correlated with waiting list death rates, transplantation rates, and MELD score at removal in all regions. In a multivariate model predicting MELD score at transplant within regions, the percentage of HCC MELD exceptions was the strongest independent predictor of regional MELD score at transplant. Conclusion: Liver transplant candidates with MELD exceptions have superior outcomes compared to nonexception candidates and the current MELD exception system is largely responsible for steadily increasing MELD scores at transplant independent of geography. (Hepatology 2015;61:285–291)

1 January 2008 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
PNP. G. Northup
P. G. Northup
VSV. Sundaram
V. Sundaram
MFM. B. Fallon
M. B. Fallon
KRK. R. Reddy
K. R. Reddy
RBR. A. Balogun
R. A. Balogun
SCS. H. Caldwell
S. H. Caldwell
A complex balance exists between endogenous procoagulants and the anticoagulant system in liver disease patients. Hypercoagulable events occur in cirrhosis patients despite the well-known bleeding diathesis of liver disease. These events may be clinically evident, such as in portal vein thrombosis or pulmonary embolism, but these conditions may also be a silent contributor to certain disease states, such as portopulmonary hypertension or parenchymal extinction with liver atrophy as well as thrombosis of extracorporeal circuits in dialysis or liver assist devices. Moreover, liver disease-related hypercoagulability may contribute to vascular disease in the increasingly common condition of non-alcoholic fatty liver disease. Despite the incidence of these problems, there are few widely accessible and practical laboratory tests to evaluate the risk of a hypercoagulable event in cirrhosis patients. Furthermore, there is little research on the use of commonly accepted anticoagulants in patients with liver disease. This article is a result of an international symposium on coagulation disorders in liver disease and addresses several areas of specific interest in hypercoagulation in liver disease. Critical areas lacking clinical information are highlighted and future areas of research interest are defined with an aim to foster clinical research in this field.

9 September 2017 in Liver International
Verified
Journal Article
Closed access
PDF file
JSJonathan G Stine
Jonathan G Stine
JWJennifer Wang
Jennifer Wang
PSPuja M. Shah
Puja M. Shah
CACurtis K. Argo
Curtis K. Argo
NINicolas Intagliata
Nicolas Intagliata
PNPatrick G. Northup
Patrick G. Northup